Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 26 May 2020, 17:16 HKT/SGT

Source: Sino Biopharmaceutical Limited
New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration

HONG KONG, May 26, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative R&D driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug (generic name: Penpulimab; R&D code: AK105) jointly developed and commercialized with Akeso, Inc. (HKEX: 9926), a biopharmaceutical company committed to R&D, production and commercialization of affordable innovative antibody drugs for patients worldwide, has been accepted by the National Medical Products Administration of the PRC, for the treatment of patients with relapsed or refractory Classical Hodgkin's Lymphoma.

Classical Hodgkin Lymphoma (cHL) is a B-cell lymphoma, and is also one of the most common malignancies among young people. It has a single modal age distribution in China with a peak at around 40 years of age . cHL is one of the few tumors that can be cured, and the most common therapy is chemotherapy plus radiotherapy, with the 5-year survival rate of patients as high as over 80%. Although the first-line chemotherapy has a high clinical cure rate, a considerable portion of patients are insensitive to chemotherapy and approximately 5% to 10% of patients do not respond to the initial treatment .

Professor Zhu Jun, Co-principal investigator of the lead unit Beijing Cancer Hospital is full of expectations for such a differentiated anti PD-1 monoclonal product and said, through bioengineering technology, Penpulimab completely eliminate the binding activity of Fc receptors and avoid the antibody-dependent cell-mediated cytotoxicity (ADCC) effect. At the same time, compared with other drugs available in the market working on the same target, it has a slower rate of antigen binding and dissociation, which makes the biological effect stronger and improves its anti-tumor activity.

Co-lead researcher Professor Song Yuqin, Director of Lymphoma Department at Peking University Cancer Hospital said, in clinical trial, Penpulimab was observed with gratifying therapeutic data and good safety. As a clinician, Professor Song hoped that Penpulimab can be launched to the market soon, which will benefit more patients and their families.

About Sino Biopharmaceutical Limited (HKEX: 1177)
Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumors, liver diseases, respiratory system diseases, anti-infectious diseases and orthopedic diseases.

Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng Index - Commerce & Industry, Hang Seng Composite Index, Hang Seng Composite Industry Index - Consumer Goods, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018.

May 26, 2020 17:16 HKT/SGT
Topic: Press release summary
Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Sino Biopharmaceutical Limited
Aug 28, 2020 17:20 HKT/SGT
Sino Biopharm Announces 2020 Interim Results
May 28, 2020 19:59 HKT/SGT
Sino Biopharmaceutical Announces 2020 First Quarterly Results
May 19, 2020 17:50 HKT/SGT
Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed by Sino Biopharmaceutical and Akeso Accepted for Presentation at ASCO Annual Meeting
Mar 30, 2020 18:25 HKT/SGT
Sino Biopharm Announces 2019 Annual Results
Jan 21, 2020 10:40 HKT/SGT
Asia-Pacific has Record Year for Clinical Trials says Novotech CRO
Nov 26, 2019 19:50 HKT/SGT
Sino Biopharmaceutical Announces 2019 Third Quarterly Results
Aug 29, 2019 16:40 HKT/SGT
Sino Biopharmaceutical Announces 2019 Interim Results
May 22, 2019 10:40 HKT/SGT
Sino Biopharmaceutical Announces 2019 First Quarterly Results
Apr 1, 2019 22:01 HKT/SGT
Sino Biopharmaceutical's 2018 Annual Results Reaches New Height
Nov 26, 2018 09:34 HKT/SGT
Sino Biopharmaceutical Announces 2018 Third Quarterly Results
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: